Atomwise Raises $45 Million Series A to Become the Preferred Artificial Intelligence Partner for the Global Pharmaceutical Industry

March 7, 2018

San Francisco, California - March 7, 2018 - Atomwise Inc. today announced it has raised $45 million of growth funding, led by Monsanto Growth Ventures, DCVC (Data Collective), and B Capital Group, in support of its mission to become the preferred artificial intelligence partner for the world’s leading pharmaceutical, biotech, and agrochemical companies. Prior investors, including Y Combinator, Khosla Ventures, and DFJ participated in the ...

Read More

Monsanto and Atomwise Collaborate to Discover New Crop Protection Options Using Artificial Intelligence Technology

June 14, 2017

St. Louis and San Francisco – (June 14, 2017) – Monsanto Company and Atomwise have formed a unique research collaboration to increase the speed and probability of discovering and developing new crop protection products using artificial intelligence. “Each growing season, farmers around the world are challenged with yield-robbing pests and diseases, yet the average crop protection product takes up to 11 years and more than $250 million ...

Read More

Atomwise Opens Applications for Historic AI Drug Discovery Awards

April 19, 2017

New initiative puts potential medicines chosen by artificial intelligence into the hands of one hundred researchers San Francisco, CA – April 19, 2017 - Atomwise Inc. seeks proposals from innovative university scientists to receive 72 potential medicines, generated specifically for their research by artificial intelligence. The Artificial Intelligence Molecular Screen (AIMS) program is designed to dramatically accelerate the race towards ...

Read More

In November, Atomwise published the first scientific paper about our technologies - AtomNet: A Deep Convolutional Neural Network for Bioactivity Prediction in Structure-based Drug Discovery. This blog post is an introduction to that work for a general audience. It assumes no prior scientific knowledge, and is greatly simplified for teaching purposes. Readers with scientific expertise should read the full paper. .ct-series-a .ct-line ...

Read More

Atomwise Raises $6 Million to Advance Artificial Intelligence for Drug Discovery

June 3, 2015

San Francisco, California - June 3, 2015 - Atomwise Inc. today announced it has raised $6 million in seed funding from five leading, science-focused venture capital firms: Data Collective, which led the funding, Khosla Ventures, DFJ, AME Cloud Ventures, and OS Fund. “Having any one of these investors behind Atomwise would be remarkable,” said Co-founder and CEO, Dr. Abraham Heifets. “Having all five is an incredible vote of confidence for ...

Read More

Atomwise finds first evidence towards new Ebola treatments

March 22, 2015

MOUNTAIN VIEW, California - March 24, 2015 - Four months ago, Atomwise launched a virtual search for safe, existing medicines that could be repurposed to treat the Ebola virus. This week, the first evidence has been found that two drugs predicted by Atomwise’s artificial intelligence technology may significantly reduce Ebola infectivity. These drugs were intended for unrelated illnesses and their potential to treat Ebola was previously ...

Read More

Atomwise Launches Search for New Ebola Treatments Using Artificial Intelligence

November 4, 2014

TORONTO, Ontario - November 4, 2014 - Atomwise Inc. and the University of Toronto announced today an initiative to search for new treatments for the Ebola virus using artificial intelligence. Deploying a groundbreaking research technology that learns and thinks like a human chemist, the team will use Canada’s most powerful supercomputer to simulate and analyze millions of potential medicines in a matter of weeks. Like software used to design ...

Read More